Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Ugeskr Laeger ; 185(6)2023 02 06.
Artigo em Dinamarquês | MEDLINE | ID: mdl-36762376

RESUMO

Neck masses are common in the paediatric population and can cause diagnostic challenges due to various differential diagnoses as summarised in this review. Neck masses in children are divided into the following categories: congenital, inflammatory/infectious and neoplastic masses. The neck masses are generally benign, but malignancy should be considered if the child is presenting with certain symptoms and findings. The objective of this review is to increase the knowledge of the common differential diagnoses of neck masses in children and to provide guidance of indications for diagnostics and treatment.


Assuntos
Neoplasias de Cabeça e Pescoço , Criança , Humanos , Neoplasias de Cabeça e Pescoço/diagnóstico , Neoplasias de Cabeça e Pescoço/terapia , Diagnóstico Diferencial , Pescoço
2.
Ugeskr Laeger ; 179(25)2017 Jun 19.
Artigo em Dinamarquês | MEDLINE | ID: mdl-28648153

RESUMO

The prevalence of oropharyngeal cancer is increasing in the Western world, and human papillomavirus (HPV) is believed to play a role in this development. Patients with HPV-positive oropharyngeal cancer differ significantly from patients with HPV-negative cancer. They may present solely with a small cervical metastasis and thus undergo an extensive diagnostic workup. Treatment modalities include radiotherapy often in combination with chemotherapy. However, new surgical advances are now possible. In this review we discuss the changing epidemiology, virology, symptomatology and different treatment modalities.


Assuntos
Neoplasias Orofaríngeas/virologia , Infecções por Papillomavirus/complicações , Adolescente , Adulto , Quimiorradioterapia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Orofaríngeas/diagnóstico , Neoplasias Orofaríngeas/epidemiologia , Neoplasias Orofaríngeas/terapia , Papillomaviridae , Infecções por Papillomavirus/diagnóstico , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/terapia , Vacinas contra Papillomavirus/administração & dosagem , Sexualidade
3.
Oncotarget ; 7(44): 71761-71772, 2016 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-27708214

RESUMO

BACKGROUND: No study has combined tumour and clinical covariates for survival to construct an individual risk-profile for overall survival (OS), time to progression (TTP), and survival after progression (SAP) in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma (OPSCC). Based on the largest-to-date, unselected, population-based cohort of patients diagnosed with OPSCC, we performed a comprehensive analysis of long-term OS, TTP, and SAP and constructed novel nomograms to evaluate patients' prognoses. RESULTS: At a median follow-up of 4.0 years (range: 0.8-15.8 yrs.), 690 deaths were recorded. The 5-year OS, TTP, and SAP for the HPV+/p16+ subgroup were 77%, 82%, and 33, vs. 30%, 66%, and 6% for the HPV-/p16- group (P < 0.01). 376 patients failed to maintain disease control with a median TTP of 13 months in the HPV+/p16+ subgroup vs. 8.5 months in the HPV-/p16- subgroup (P < 0.05). HPV combined with p16 status remained one of the most informative covariates in the final Cox regression model for OS, TTP, and SAP. METHODS: We included all patients diagnosed with OPSCC (n = 1,542) between 2000-2014 in Eastern Denmark. Survival rates were estimated by the Kaplan-Meier method. A multivariate Cox regression model was used to construct predictive, internally validated nomograms. CONCLUSION: The HPV+/p16+ subgroup had improved OS, TTP, and SAP compared with other combinations of HPV and p16 after adjusting for covariates. Nomograms were constructed for 1-, 5- and 10-year survival probability. Models may aid patients and clinicians in their clinical decision making as well as in counselling, research, and trial design.


Assuntos
Neoplasias Orofaríngeas/mortalidade , Papillomaviridae/isolamento & purificação , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Nomogramas , Neoplasias Orofaríngeas/virologia , Modelos de Riscos Proporcionais , Adulto Jovem
4.
Otolaryngol Head Neck Surg ; 155(3): 387-90, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27165680

RESUMO

OBJECTIVE: The orbital blowout fracture is a common facial injury, carrying with it a risk of visual impairment and undesirable cosmetic results unless treated properly. Optimal timing of the surgical treatment is still a matter of debate. We set out to determine whether a meta-analysis would bring us closer to an answer to this question. DATA SOURCES: PubMed, EMBASE, Web of Science, and the Cochrane Library were searched from January 1980 to August 2014. We applied the following inclusion criteria: isolated blowout fractures, presenting early and late surgery groups (<14 and >14 days). Patients were evaluated for diplopia and enophthalmos. REVIEW METHODS: We followed the statements of PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses). Pooled odds ratios were estimated with the fixed effects method of Mantel-Haenszel. RESULTS: We identified 5 studies with available outcome data (N = 442). Patients in the late group showed an odds ratio of 3.3 (P = .027) for persistent postoperative diplopia as compared with the early group. We found no significant difference between the groups when assessing postoperative enophthalmos as an isolated symptom. CONCLUSION: We found a significantly increased risk of persistent diplopia in patients who were operated >14 days after the trauma.


Assuntos
Fraturas Orbitárias/cirurgia , Diplopia/etiologia , Enoftalmia/etiologia , Humanos , Complicações Pós-Operatórias/etiologia , Fatores de Tempo
5.
Ugeskr Laeger ; 178(10): V08150649, 2016 Mar 07.
Artigo em Dinamarquês | MEDLINE | ID: mdl-26957411

RESUMO

The risk of complications warrants treatment of most dislocated nasal fractures. Other injuries including other facial fractures and septal haematoma must be treated if present at the initial presentation. The usual treatment for a simple nasal fracture is closed reduction in local anaesthesia after five to seven days. Complicated cases require open reduction in general anaesthesia. Later revision of the deviated nose may become necessary in patients suffering from complications such as persistent nasal stenosis and/or deformity.


Assuntos
Osso Nasal/lesões , Fraturas Cranianas , Adulto , Humanos , Fraturas Cranianas/diagnóstico , Fraturas Cranianas/terapia
8.
Ugeskr Laeger ; 177(39): V02150131, 2015 Sep 21.
Artigo em Dinamarquês | MEDLINE | ID: mdl-26418637

RESUMO

Doctors are frequently presented to patients with a neck mass, and the condition might cause diagnostic challenges. In younger adults, a neck mass can typically be explained by congenital, inflammatory or infectious causes. The highest probability of neoplasms is found in patients above 40 years of age. When a malignant neoplasm in the neck is suspected, patients should be referred to an ear, nose and throat specialist. In cases of suspect signs of malignancy as defined by the Danish Health and Medicines Authority, patients should be referred to the integrated national cancer pathways.


Assuntos
Neoplasias de Cabeça e Pescoço/diagnóstico , Pescoço/patologia , Adulto , Cistos/patologia , Diagnóstico Diferencial , Neoplasias de Cabeça e Pescoço/terapia , Departamentos Hospitalares , Humanos , Infecções/diagnóstico , Pescoço/anatomia & histologia , Otolaringologia
10.
Am J Rhinol Allergy ; 29(3): 193-201, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25975250

RESUMO

BACKGROUND: Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) and asthma are strongly associated, and patients suffering from both diseases are often difficult to treat. However, no guidelines about the management of patients with CRS and coexisting asthma exist. OBJECTIVE: The purpose of this systematic review was to evaluate the management of CRSwNP and coexisting asthma. METHODS: We systematically searched electronic databases and included clinical trials in which the clinical outcomes after medical or surgical treatment of patients with CRSwNP and asthma were assessed. The strength of the evidence for each outcome was graded on the basis of study quality and consistency in findings. RESULTS: We included seven trials in which the effect of montelukast, omalizumab, erythromycin, and functional endoscopic sinus surgery (FESS) were studied in 317 adults with CRSwNP and asthma. All the interventions improved the majority of subjective and objective nasal outcomes significantly. However, few studies found significant effects on pulmonary function tests. The strength of the evidence was low overall. CONCLUSION: Both FESS and medical interventions with systemic anti-inflammatory drugs improved nasal outcomes, although their efficacy in relation to the lower airways remains unclear. A low number of studies met inclusion criteria for this systematic review, which emphasizes the need for high-quality trials to explore the treatment of patients with CRSwNP and coexisting asthma.


Assuntos
Asma/epidemiologia , Asma/terapia , Pólipos Nasais/epidemiologia , Pólipos Nasais/terapia , Rinite/epidemiologia , Rinite/terapia , Sinusite/epidemiologia , Sinusite/terapia , Acetatos/uso terapêutico , Antiasmáticos/uso terapêutico , Doença Crônica , Ciclopropanos , Endoscopia , Humanos , Antagonistas de Leucotrienos/uso terapêutico , Pólipos Nasais/cirurgia , Omalizumab/uso terapêutico , Qualidade de Vida , Quinolinas/uso terapêutico , Rinite/cirurgia , Sinusite/cirurgia , Sulfetos
12.
J Thorac Oncol ; 9(6): 865-71, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24787962

RESUMO

INTRODUCTION: This review investigates the role of p16(INK4a) as a marker of transcriptionally active human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) and the regional prevalence of HPV in ESCC. METHODS: PubMed, EMBASE, and the Cochrane Library were systematically searched with the purpose of identifying all studies published between January 1980 and July 2013 reporting both HPV and p16 results in a minimum of five human ESCC specimens. RESULTS: Twelve studies were identified, providing data on a total of 1383 ESCC specimens collected between 1987 and 2009 from 10 different countries. HPV DNA was detected in 12.0% (n = 161) of 1347 specimens, and p16(INK4a) was detected in 33.9% (n = 209) of 617 specimens. The HPV presence varied from 0% to 70% among the studies. The prevalence of p16(INK4a) overexpression in HPV-positive and HPV-negative specimens demonstrated no statistically significant difference, neither for the combined data (p = 0.7507) nor for any individual study, and detection of p16(INK4a) overexpression did not affect the odds of tumors being HPV positive (odds ratio = 1.0666 with 95% confidence interval 0.7040-1.6157). In a pooled analysis, the sensitivity of p16(INK4a) overexpression as a marker of HPV DNA presence was 0.35, the specificity 0.67, and the positive predictive value 0.25. CONCLUSIONS: This systematic review reports great regional variation in the prevalence of HPV in ESCC and suggests that p16(INK4a) is not a reliable marker of HPV status in ESCC.


Assuntos
Carcinoma de Células Escamosas/química , Inibidor p16 de Quinase Dependente de Ciclina/análise , DNA Viral/análise , Neoplasias Esofágicas/química , Papillomaviridae/isolamento & purificação , Infecções por Papillomavirus/epidemiologia , Biomarcadores/análise , Carcinoma de Células Escamosas/virologia , Neoplasias Esofágicas/virologia , Humanos , Papillomaviridae/genética , Infecções por Papillomavirus/complicações , Valor Preditivo dos Testes , Prevalência
13.
Eur J Dermatol ; 23(6): 774-81, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24334009

RESUMO

BACKGROUND: Real-life data on the therapeutic effectiveness and costs of etanercept are scarce. OBJECTIVES: To assess the clinical and economic impact of etanercept in patients with psoriasis in Denmark and Norway. MATERIAL & METHODS: This prospective, non-interventional study in a private dermatologist care setting in Denmark and Norway included patients ≥18 years with moderate to severe plaque psoriasis, selected for treatment with etanercept. Assessments during 1 year from etanercept initiation included Dermatology Life Quality Index (DLQI), Self-Administered Psoriasis Area and Severity Index (SAPASI) and adverse events. Direct and indirect costs were calculated. RESULTS: 163 subjects were enrolled. Baseline mean SAPASI was 19.1 . Proportion of patients with ≥50% decrease in SAPASI from baseline was 85% and 81% at weeks 24 and 52. DLQI decreased significantly from 11.4 (7.0) to 3.2 (4.3) and 3.7 (4.6) at weeks 24 and 52. Total annual costs increased from 78,000 to 286,000 DKK (p<0.0001), mainly due to the cost of etanercept. Outpatient-care costs and loss-of-productivity costs decreased from 9,500 to 5,000 (p = 0.0002), and from 33,000 to 18,000 DKK (p = 0.0105), respectively. The decrease in costs was more pronounced in patients who also had psoriatic arthritis. Cost increase was greatest during the first 6 months. CONCLUSION: Etanercept treatment was associated with decreased psoriasis severity and improved quality of life. Cost increase was driven by medication, while costs of outpatient care and loss-of-productivity decreased. Maintained improved quality of life was accompanied by decreasing cost during the second 6 month period of etanercept treatment. There were no new safety signals reported.


Assuntos
Anti-Inflamatórios não Esteroides/economia , Anti-Inflamatórios não Esteroides/uso terapêutico , Efeitos Psicossociais da Doença , Imunoglobulina G/economia , Imunoglobulina G/uso terapêutico , Psoríase/tratamento farmacológico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Adulto , Assistência Ambulatorial/economia , Anti-Inflamatórios não Esteroides/efeitos adversos , Dinamarca , Custos de Medicamentos/estatística & dados numéricos , Etanercepte , Feminino , Custos de Cuidados de Saúde/estatística & dados numéricos , Humanos , Imunoglobulina G/efeitos adversos , Masculino , Pessoa de Meia-Idade , Noruega , Prática Privada/economia , Estudos Prospectivos , Qualidade de Vida , Índice de Gravidade de Doença
16.
Exp Dermatol ; 13(4): 265-71, 2004 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15086343

RESUMO

TARC/CCL17 (thymus- and activation-regulated chemokine) is a CC chemokine, which binds to the CC chemokine receptor-4 (CCR4) known to be distinctively expressed on Th2 lymphocytes. In atopic dermatitis (AD), the skin is invaded by Th2 lymphocytes in the acute phase. TARC/CCL17 is produced by the keratinocytes in AD lesions, and CCR4 is overexpressed on CLA+ (cutaneous lymphocyte-associated antigen) lymphocytes in the skin and blood. We, therefore, hypothesized that TARC/CCL17 is pivotal in mediating a Th2-dominated inflammation in the skin. To examine this, we injected BALB/c mice with murine TARC/CCL17 in concentrations ranging from 0.1 microg/ml to 10 microg/ml and examined the skin after 48 h. This revealed that TARC/CCL17 induces lymphocytic infiltration of the skin by CD4+ lymphocytes in a dose-dependent manner with a maximum response at 1 microg/ml. Additionally, TARC/CCL17 induced interleukin-4 mRNA but not interferon-gamma mRNA expression in the skin, suggesting that the lymphocytes invading the skin are Th2 cells. Additionally, TARC/CCL17 induced its own production in the keratinocytes along with cutaneous T-cell-attracting chemokine (CTACK/CCL27) mRNA. We, therefore, conclude that TARC/CCL17 induces a Th2-dominated inflammatory reaction when injected into the skin.


Assuntos
Quimiocinas CC/farmacologia , Dermatite Atópica/etiologia , Células Th2/efeitos dos fármacos , Células Th2/imunologia , Animais , Sequência de Bases , Quimiocina CCL17 , Quimiocinas/genética , Quimiocinas CC/administração & dosagem , Quimiocinas CC/genética , Citocinas/genética , DNA/genética , Dermatite Atópica/imunologia , Dermatite Atópica/patologia , Feminino , Humanos , Injeções Intradérmicas , Camundongos , Camundongos Endogâmicos BALB C , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptores de Quimiocinas/genética , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacologia , Células Th2/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA